Click Therapeutics reports positive Phase 3 clinical data for CT-132, a digital therapeutic intended as an adjunctive treatment of episodic migraine. The company is pursuing FDA clearance and actively exploring opportunities to offer a drug-digital combination therapy with added clinical benefit that provides “a single, integrated experience for the patient, prescriber and payer.”

This week, two device testing labs in China landed FDA warning letters; refunds for 1Health.io clients; FDA AR/VR product list expands. 

The firm’s dual-chamber leadless pacemaker system with is expected to be a growth driver for Abbott and already has acquired approximately 30%-40% of market share from Medtronic since its approval by the US FDA in July 2023, according to GlobalData.

Apple is introducing new health features in conjunction with its launch of the Series 10 Apple Watch and AirPods Pro 2 earbuds, which soon will be able to monitor for potential sleep apnea and function as a clinical-grade hearing aid, respectively, pending regulatory clearances in the US and other countries around the globe.

Apple is introducing new health features in conjunction with its launch of the Series 10 Apple Watch and AirPods Pro 2 earbuds, which soon will be able to monitor for potential sleep apnea and function as a clinical-grade hearing aid, respectively, pending regulatory clearances in the US and other countries around the globe.

Edwards Lifesciences’ Critical Care business “invented the hemodynamic monitoring category, and its solutions are currently used in more than 10,000 hospitals globally to better understand the cardiovascular condition in real-time for critically ill patients, which helps improve outcomes,” says BD, which sees synergies and new innovation opportunities across the groups’ data sets and platforms. Acquired for $4.2bn cash, Critical Care generated more than $900m in revenue in 2023.